Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Neurotrauma topics
3. Brain and spinal cord injury research
4. Bench to bedside/bedside to bench research
5. Therapeutic opportunities
6. TBI epidemiology
7. Primary injury
8. Brain after TBI (1)
9. Brain after TBI (2)
10. Secondary insults
11. Types of secondary injury mechanisms
12. Types of brain injury
13. Types of preclinical animal models of TBI
14. Weight drop model
15. Impact acceleration model (Marmarou device)
16. Controlled cortical impact (CCI)
17. Fluid-percussion brain injury
18. Blast injury model
19. Induction of traumatic brain injury
20. TBI pathology
21. Lack of treatments
22. Therapeutic hypothermia
23. History of hypothermia
24. Treatment with induced hypothermia
25. Whole-body hypothermia for neonates
26. Does moderate hypothermia protect in TBI?
27. Neuronal cell death/contusion
28. Glutamate levels affected by hypothermia
29. Post traumatic inflammation
30. Temperature mechanisms in ischemia and trauma
31. Fever in the neuro ICU
32. Temperature changes following TBI
33. Hyperthermia affects mortality/contusion volume
34. Spectrum of brain trauma heterogeneous injury
35. Therapeutic hypothermia
36. Morris water maze
37. Hypothermia therapy improves cognition after TBI
38. Protein kinases involved in learning and memory
39. Drugs tested to improve cognition
40. Posttraumatic epilepsy
41. Hippocampus staining from epileptic patient
42. Mossy fiber sprouting
43. Hypothermia reduces seizure susceptibility
44. Hypothermia attenuates axonal sprouting
45. Trials conducted using hypothermia after TBI
46. Long/short term hypothermia after TBI
47. Questions regarding therapeutic hypothermia
48. Progesterone clinical trials
49. Spinal cord injury
50. MRI images in rodents, porcine and man
51. Diffusion tensor imaging
52. SCI epidemiology
53. Pathophysiology of acute spinal cord injury
54. CT scan of extreme SCI
55. Acute SCI - secondary injury mechanisms
56. Cellular events that occur after SCI
57. Cytoprotection
58. Neuroprotective agents
59. NASCIS III studies
60. Sygen (GM-1 Ganglioside) summary of findings
61. Promising treatments targeting CNS injury
62. Confirming experimental therapies
63. The history of hypothermia for SCI
64. Effects of SC cooling in experimental SC trauma
65. Spinal cord modest hypothermia
66. Is modest hypothermia protective in SCI
67. Thoracic injury
68. Clinical protocols for therapeutic hypothermia
69. Hypothermia and human SCI
70. Research protocol at UMMSM/JMH
71. Application of modest hypothermia after SCI
72. Cooling profile of SCI patient
73. ASIA impairment scale
74. Modest intravascular hypothermia after SCI
75. Clinical trials to test the novel therapy
76. Acute rapid cooling therapy for SCI
77. Repairing the spinal cord after injury
78. The complicated nature of SCI
79. Regeneration obstacles and strategies
80. Using helper cells to promote regeneration
81. Cell therapy
82. The potential use of Schwann cells
83. Advantages of Schwann cells in SCI
84. A Schwann cell bridge
85. Schwann cells transplanted into an injured site
86. Schwann cells bridge plus ensheathing glia
87. Triple therapy - Schwann cell, Rolipram, cAMP
88. Elevating cAMP promotes axonal growth
89. Schwann cell therapy in clinical trials
90. Proposed human Schwann cell clinical trial
91. Trial parameters
92. Technical milestones for human Schwann cell trial
93. Stem cells as therapy in SCI - timeline
94. Embryonic stem cell-derived oligodendrocyte
95. FDA approves GRNOPC1 IND first patient treated
96. Allodynia after neural stem cell transplantation
97. Stem cell therapy triggers tumor formation
98. Promoting regeneration
99. Growth promoting factors
100. Regenerating axons face two major barriers
101. Inhibitory CNS environment
102. Innovative technologies
103. Automated microscope for phenotypic screening
104. High content screening in primary neurons
105. Chemical library
106. Automated analysis of neurons and processes
107. The microscope looks at many types of fields
108. Large scale screens
109. KLFs and axon regeneration
110. Most of the KLFs affect axon growth
111. KLF4 KO leads to increased axon regeneration
112. Various clinical research programs
113. Conditioning approaches
114. Cardiovascular and robotic training
115. Manual rehabilitation approaches
116. Combination therapy
117. Summary
118. The Miami Project faculty
119. Thank you

Topics Covered

• Brain and spinal cord trauma
• Epidemiology of the clinical condition
• Animal modeling approaches
• Pathophysiological mechanisms of CNS injury
• Clinically relevant outcome measures
• Neuropathology
• Behavioral outcomes
• Clinical trials
• Novel treatments

Links

Series:

• Neurotrauma

Categories:

• Clinical Practice
• Neuroscience

Therapeutic Areas:

• Neurology

Talk Citation

Dietrich, W.D. (2011, November 23). Experimental approaches to developing and evaluating novel treatments for TBI and SCI [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/VCQD1874.
Export Citation (RIS)

Publication History

• Published on November 23, 2011

Financial Disclosures

• Prof. W. Dalton Dietrich has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.